WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac.
Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac.
Product Overview |
|||
Vaccine type: |
COVID-19 Vaccine (Vero Cell), Inactivated |
||
Commercial name: |
CoronaVac |
||
EUL holder: |
Sinovac Life Sciences Co., Ltd. |
||
Country: |
China |
||
URL: |
|||
Manufacturing sites: |
Sinovac Life Sciences Co., Ltd. No. 21, Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R. China |
||
Responsible NRA: |
National Medical Products Administration (NMPA) |
||
Country: |
China |
||
URL: |
|||
WHO Recommendation |
|||
Effective date: |
01 June 2021 |
||
Product Description |
|||
Pharmaceutical form: |
Suspension for injection |
||
Presentation: |
Vial/non-auto disabled single use prefilled syringe |
||
Number of doses: |
1 and 2 |
||
Diluent: |
Not applicable |
||
Route of administration: |
Intramuscular |
||
Shelf-life: |
12 months |
at storage temperature: |
2-8°C |
Special conditions for storage: |
Not applicable |
||
Vaccine Vial Monitor: |
Not applicable |
||
Packaging: |
For vials:a) One (1) dose x vial Secondary Packaging: Tertiary packaging: b) Two (2) doses x vial Secondary Packaging: Tertiary packaging: For Prefilled syringe:Monodose 1 x PFS Secondary Packaging: Tertiary packaging: |
||
Secondary and Tertiary packaging: |
see under Packaging |
||
Cold Chain Volume per dose in cm3 (in secondary packaging): |
Vials PFS |
||
Preservative: |
Not applicable |
with concentration: |
Not applicable |
Handling of opened multidose-vials: |
Not applicable |